Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCA-1: Cytisinicline in Adult Smokers
NCT03709823Phase 2Completed
- Sponsor
- Achieve Life Sciences
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cytisinicline in nicotine dependence (6 arms), sponsored by Achieve Life Sciences. Primary endpoint: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment. Started Nov 2018; status: completed.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT03709823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709823.